Need real exam questions of 00M-648 exam? Download here.
killexams.com is a extremely worthy website on line for 00M-648 certification dump. Whilst i establish you on the net, I almost joyed in enjoyment because it turned into exactly what i used to be looking for. I used to be searching out some exact and less expensive succor online because of the reality I didnt savor the time to Go through bunch of books. I establish adequate test question perquisite here that proved to be very beneficial. I was able to marks rightly in my IBM test and Im obliged.
You just necessity a weekend to prepare 00M-648 exam with these dumps.
I used this bundle for my 00M-648 exam, too and passed it with top score. I relied on killexams.com, and it was the perquisite conclusion to make. They give you real 00M-648 exam questions and answers just the passage you will behold them on the exam. Accurate 00M-648 dumps are not available anywhere. Dont depend on free dumps. The dumps they provided are updated any the time, so I had the latest information and was able to pass easily. Very worthy exam preparation
here are hints & hints with dumps to certify 00M-648 examination with immoderate scores.
Hurrah! i savor passed my 00M-648 this week. and that i got flying color and for any this i am so grateful to killexams. they savor got Come up with so confiscate and well-engineered software. Their simulations are very just enjoy the ones in real tests. Simulations are the primary component of 00M-648 exam and really worth extra weight age then other questions. After making ready from their program it turned into very smooth for me to remedy any the ones simulations. I used them for any 00M-648 exam and located them trustful each time.
No more worries even as making equipped for the 00M-648 exam.
Even as i used to be getting organized up for my 00M-648 , It became very annoying to pick out the 00M-648 test material. I discovered killexams.com while googling the trait certification assets. I subscribed and noticed the wealth of sources on it and used it to prepare for my 00M-648 check. I clean it and Im so thankful to this killexams.com.
So smooth coaching brand modern 00M-648 exam with this question bank.
I wound up the exam with a fulfilling 84% marks in stipulated time. Thanks very plenty killexams. Through and by means of, it grow to be difficult to accomplish top to bottom observe proceeding with a full-time work. At that factor, I became to the of killexams. Its concise solutions helped me to behold a few complicated subjects. I selected to sit for the exam 00M-648 to attain in addition development in my career.
Unbelieveable! however perquisite source modern day 00M-648 real test questions.
I savor been the usage of the killexams.com for a while to any my tests. Closing week, I passed with a outstanding marks in the00M-648 exam through manner of using the examine sources. I had a few doubts on topics, however the material cleared any my doubts. i savor with out troubles determined the reply for any my doubts and troubles. Thank you for imparting me the stable and reliable material. Its miles the nice product as I understand.
Try out these 00M-648 dumps, It is Awesome!
I passed the 00M-648 certification today with the succor of your provided Questions answers. This blended with the course that you savor to assume which will emerge as a certified is the manner to go. in case you accomplish but suppose that just remembering the questions and answers is any you necessity to skip rightly you are wrong. There savor been quite a few questions aboutthe exam that arent inside the provided QA however if you prepare a lot of these Questions answers; you may strive the ones very easily. Jack from England
I sense very assured with 00M-648 exam bank.
I handed 00M-648 certification with ninety one percentage marks. Your braindumps are very similar to actual exam. Thank you for your greatassist. I am capable of retain to consume your dumps for my subsequent certifications. At the identical time as i used to be hopeless that i cant emerge as an IT licensed; my pal advised me about you; I attempted your on line education equipment for my 00M-648 examand emerge as capable of earn a 91 result in exam. I personal passage to killexams.
just try those real exam questions and success is yours.
The customary of killexams.com is immoderate adequate to assist the candidates in 00M-648 exam training. any the goods that I had used for 00M-648 exam training were of the first rate remarkable in order that they assisted me to smooth the 00M-648 exam rapidly.
determined maximum 00M-648 Questions in actual exam that I organized.
I never concept I must skip the 00M-648 exam. But im one hundred% certain that with out killexams.com i savor not accomplished it very well. The impressive dump affords me the desired capability to assume the exam. Being intimate with the supplied dump I handed my exam with 90 two%. I never scored this an lousy lot sequel in any exam. Its far rightly feeling out, effective and reliable to use. Thanks for presenting a dynamic dump for the getting to know.
A month has passed by due to the fact the final salary file for IBM (IBM). Shares savor brought about 3.9% in that time frame, underperforming the S&P 500.
Will the synchronous fine trend continue leading up to its subsequent salary unencumber, or is IBM due for a pullback? before they dive into how traders and analysts savor reacted as of late, let's assume a quick seem on the most synchronous revenue record as a passage to earn a stronger deal with on the captious drivers.
IBM q4 salary Beat Estimates, Revenues Decline Y/Y
foreign traffic Machines Corp delivered fourth-quarter 2018 non-GAAP revenue of $4.87 per share, which beat the Zacks Consensus assay of $four.81 per share. besides the fact that children, salary per participate (EPS) decreased 5.9% from the yr-in the past quarter. The 12 months-over-yr decline in EPS may moreover be attributed to bigger tax rate.
Revenues of $21.76 billion savor been pretty much in response to the Zacks Consensus assay of $21.seventy four billion and declined three.5% on a yr-over-yr groundwork. At consistent alien money (cc), revenues dipped 1%. The yr-over-year decline can basically be attributed to currency fluctuation and headwinds from IBM Z product cycle.
above all, IBM pointed out that signings surged 21% on cc groundwork to $15.8 billion. features backlog declined 1% yr over yr and got here in at $116 billion.
Geographic salary particulars
Revenues from Americas had been down four%, reflecting the headwind from the IBM Z product cycle. despite the fact, continued extend in Latin america changed into a favorable.
Europe, middle-East and Africa expanded 2% from the year-in the past quarter principally because of growth in Spain, Germany, Italy and the U.k.
Asia-Pacific revenues declined 1% on a yr-over-12 months basis with modest extend in Japan.
Strategic Imperatives extend Continues
Strategic Imperatives (cloud, analytics, mobility and security) grew 5% at cc from the 12 months-ago quarter to $11.5 billion. with the exception of IBM Z product cycle influence Strategic Imperatives grew eleven% yr over 12 months.
safety revenues surged 17% (with the exception of IBM Z product cycle savor an sequel on) and declined three% on cc groundwork. On a trailing 12-month foundation, Strategic Imperatives revenues were $40 billion, up 9%.
Cloud revenues surged 6% from the year-ago quarter to $5.7 billion and 19% (aside from IBM Z product cycle influence). The annual sprint rate for cloud as-a-service revenues accelerated 21% at cc on a 12 months-over-yr foundation to $12.2 billion.
Cloud revenues of $19.2 billion on a trailing 12-month groundwork accelerated 12% yr over 12 months.
Cognitive Revenues Surge
Cognitive solutions’ revenues-exterior improved 2% year over year (on cc groundwork) to $5.5 billion. Revenues from Cognitive solutions (together with options utility and transaction processing) improved essentially because of growth in options application, including analytics and synthetic intelligence (AI).
Segmental revenues touching on Strategic Imperatives and Cloud increased 9% and 5%, respectively. Cloud as-a-provider salary annual sprint fee was $2 billion.
solutions software comprises offerings in strategic verticals enjoy health, area-certain capabilities enjoy analytics and protection, and IBM’s rising technologies of AI and blockchain. The section additionally comprises offerings that wield horizontal domains enjoy collaboration, commerce and skill. within the pronounced quarter, options application revenues accelerated three% yr over yr.
IBM stated that the integration of AI into offerings enjoy consumer adventure analytics in commerce zone helped SaaS signings to develop in double digit in the mentioned quarter.
Transaction Processing application includes software that runs mission-important workloads, leveraging IBM’s hardware systems. Revenues savor been up 1% on a 12 months-over-yr basis.
IBM witnessed extend in industry verticals enjoy fitness, key areas of analytics and protection in the quarter. Watson fitness witnessed extensive-based mostly extend in Payer, company, Imaging and life Sciences domains.
all through the fourth quarter, IBM extended partnership with Vodafone community. Per the deal, IBM’s advanced hybrid cloud platform, AI, web of things (“IoT”) capabilities will assist Vodafone traffic with digital transformation initiatives.
IBM brought up that analytics carried out well within the quarter, driven through facts science choices and IBM Cloud deepest for statistics offering.
protection boom became driven via offerings in orchestration, records safety and endpoint management.
In blockchain, IBM introduced addition of a brace of modern customers any over the quarter, which includes “work with wise Dubai on the focus East’s first government-recommended blockchain platform.” The traffic additionally unveiled an on-prem providing throughout the stated quarter, the IBM Blockchain Platform for IBM Cloud deepest. several modern deal wins is moreover assisting IBM to reinforce its foothold in blockchain technology.
international traffic functions Revenues increase
Revenues from world company features-exterior section had been $four.3 billion, up 4% from the yr-in the past quarter (up 6% at cc). The yr-over-12 months boost changed into essentially because of extend across any three enterprise areas specifically consulting, utility administration and global technique functions.
Segmental revenues mien on Strategic Imperatives grew 14%. Cloud drill surged 34%. Cloud as-a-carrier salary annual sprint rate become $2.1 billion.
application management revenues expanded four% from the year-in the past quarter. international system functions revenues climbed 5%. in addition, Consulting revenues multiplied 10% year over year, pushed through powerful efficiency from IBM’s digital business.
know-how services & Cloud platforms: Revenues Dip
Revenues from expertise capabilities & Cloud structures-exterior decreased 3% from the 12 months-in the past quarter (flat at cc) to $eight.9 billion. Segmental revenues touching on Strategic Imperatives advanced 13%, pushed via hybrid cloud features. Cloud surged 22% from the yr-in the past quarter. Cloud as-a-carrier salary annual sprint expense was $eight billion.
Integration application improved four% from the year-ago quarter. perquisite through the suggested quarter, more than 100 corporations world wide selected IBM Cloud private offering. Infrastructure functions revenues had been flat on a yr-over-yr groundwork.
Technical steer features revenues diminished three% from the 12 months-ago quarter.
vigor & z14 drive programs Revenues
methods revenues diminished 21% on a 12 months-over-yr foundation (down 20% at cc) to $2.6 billion, essentially because of savor an sequel on of the IBM Z product cycle. Segmental revenues relating Strategic Imperatives plunged 22%, while Cloud revenues declined 31%.
IBM Z revenues decreased 44% year over yr. despite the fact, MIPS ability has increased around 20%, pushed by means of huge-based adoption of the z14 mainframe.
vigor revenues multiplied 10% from the 12 months-in the past quarter. The upside was principally because of Linux and robust adoption across the latest POWER9-primarily based structure.
during the fourth quarter, IBM completed the launch of its subsequent generation POWER9 processors for midrange and high-conclusion methods that are designed for dealing with superior analytics, cloud environments and information-intensive workloads in AI, HANA, and UNIX markets.
IBM additionally introduced modern offerings optimizing both hardware and application for AI. management believes that products enjoy PowerAI imaginative and prescient and PowerAI enterprise will assist drive modern customer adoption.
besides the fact that children, storage hardware revenues declined as a result of vulnerable efficiency in the mid-range conclusion, partially offset by passage of mighty growth in any glitter Arrays. IBM cited that pricing obligate within the immensely aggressive storage market is hurting revenues. The enterprise announced its modern FlashSystems with next generation NVMe expertise any over the reported quarter.
working programs software revenues declined 3%, while techniques Hardware slumped 23% from the yr-ago quarter.
at last, global Financing (contains financing and used gadget income) revenues reduced 11% 12 months over year and 9% at cc to $402 million.
Non-GAAP low margin remained unchanged from the 12 months-ago quarter at forty nine.5%. The low margin benefited primarily by passage of 190 basis elements (bps) growth in services margin. despite the fact, detrimental combine in IBM Z product cycle fully offset this enlargement.
operating expense declined 5.3% yr over 12 months, because of cognizance of acquisition synergies and enhancing operational efficiencies. IBM continues to invest in unexpectedly starting to be fields enjoy hybrid cloud, synthetic intelligence (AI), protection and blockchain.
Pre-tax margin from carrying on with operations multiplied 50 bps on a 12 months-over-year foundation to 23.1%.
Cognitive options and global enterprise services section pre-tax margins increased 290 bps and 520 bps, respectively, on a year-over-yr foundation. despite the fact, expertise capabilities & Cloud systems segment pre-tax margin shriveled 20 bps.
Non-GAAP operating margins from carrying on with operations reduced in size ninety bps and came in at 20.3%.
steadiness Sheet & money circulate particulars
IBM ended fourth-quarter 2018 with $eleven.ninety nine billion in total cash and marketable securities in comparison with $14.70 billion on the conclude of third-quarter 2018. complete debt (together with present component) changed into $forty five.eight billion, down from $forty six.9 million from the outdated quarter.
IBM reported money slither from operations (excluding world Financing receivables) of $7.3 billion and generated free cash stream of $6.5 billion in the quarter under evaluation.
within the mentioned quarter, the enterprise back $3.5 billion to shareholders via dividends and participate repurchases. The enterprise back more than $10 billion to shareholders through dividends and participate repurchases for the complete fiscal yr.
on the conclusion of the year, the company had $3.3 billion remaining beneath latest buyback authorization.
Fiscal 2018 Highlights
IBM said fiscal 2018 non-GAAP earnings of $13.eighty one per share, where as revenues came in at $79.6 billion, up 1% every year over yr.
Revenues from Cognitive solutions, international enterprise services, know-how features & Cloud platforms, systems and international Financing got here in at $18.forty eight billion, $16.eighty two billion, $34.forty six billion, $eight.03 billion and $1.fifty nine billion, respectively.
IBM expects non-GAAP EPS forecast for 2019 to be at least $13.ninety.
IBM still anticipates 2019 free money circulation of $12 billion.
How savor Estimates Been moving when you consider that Then?
It seems, sparkling estimates flatlined perquisite through the past month.
at the present, IBM has a subpar boom rating of D, however its Momentum ranking is doing lots better with a B. Charting a slightly an identical path, the inventory was allocated a grade of A on the cost aspect, inserting it in the exact quintile for this funding method.
overall, the stock has an combination VGM ranking of B. in case you don't seem to be focused on one strategy, this score is the one be certain to be interested in.
IBM has a Zacks Rank #three (cling). They predict an in-line recrudesce from the stock within the next few months.
want the latest options from Zacks investment analysis? nowadays, that you can download 7 top-rated stocks for the subsequent 30 Days. click on to earn this free document international company Machines service provider (IBM) : Free inventory analysis record To study this text on Zacks.com click on here. Zacks investment research
each Microsoft (NASDAQ:MSFT) and IBM (NYSE:IBM) savor needed to shift their strategies in recent years to preserve providing boom for shareholders. however, despite slowing pc income and competitors from Apple, Microsoft has had a ways improved success than IBM in maintaining its traffic momentum going. Microsoft is customary for its dominance with its windows operating equipment and workplace application, however over the ultimate two years, it has emerged as probably the most largest cloud suppliers on earth.
IBM is investing heavily within the cloud, too, however it's struggling to retain up with quick-transforming into tech competitors, including Microsoft. Of course, the determination to purchase both of these stocks may still be based on more than simply who is growing faster within the cloud area. they will compare both organizations' fiscal positions, valuations, dividends, and most significantly, their competitive positions to check which is the superior buy today.financial fortitude
A assessment of an organization's monetary fitness tells buyers greater than in basic terms which traffic can hold up more desirable any the passage through periods of softening in the financial system. a corporation with robust monetary fortitude has greater opportunities to convey returns to shareholders through constructing modern items, making earnings-constructing acquisitions, or paying a rising dividend over time.
With that in intellect, here's a overview of how both organizations measure up on key monetary metrics:Metric Microsoft IBM money $127.66 billion $12 billion Debt $73.17 billion $45.18 billion salary (TTM) $118.forty six billion $seventy nine.59 billion Free cash stream (TTM) $31.9 billion $11.fifty three billion Free cash circulation as a percentage of profits 26.9% 14.5%
Microsoft is naturally the winner on this captious check. The application massive has about $54.5 billion of net cash, after subtracting debt, whereas IBM has extra debt than cash.
Winner: Microsoft.Valuation and dividends
a higher-buy assessment is never finished devoid of due to the fact that valuation. evaluating these two shares on quite a number universal metrics will succor assume faith of against overpaying for an organization's profits. here's how shares of Microsoft and IBM stack up:Metric Microsoft IBM Trailing P/E 25.1 14.fifty one forward P/E 21.7 9.seventy four PEG ratio 1.seventy two 10.22 price-to-free money flow 26.four 10.97 Dividend yield 1.72% four.6% Dividend payout as a percentage of free money circulation 41.forty four% forty nine.14%
at first glance, IBM looks just enjoy the improved cost. however, retain in mind, analysts await great Blue to develop profits by 1% per 12 months over the next 5 years, so the enterprise's low fee-to-revenue numerous may still include a warning label. even so, analysts are expecting Microsoft to develop revenue by means of 14% per yr going ahead -- that is why Microsoft has a lessen PEG (expense-to-profits-increase) ratio.
even so, any improvement in IBM's salary growth would probably trigger buyers to alter their expectations, which would transmit huge Blue's stock fee better. So, i'll provide IBM the profit of the doubt.
taking a examine at dividends, IBM seems just enjoy the winner. It pays a juicy yield, which salary buyers should still find appealing. however once more, caution is warranted.
I lately made the controversy that Microsoft is a stronger dividend boom inventory than IBM, and that i'm sticking to it. IBM's capitulate is tempting, but Microsoft has really grown its dividend at a sooner cost than IBM in recent years. in the meantime, IBM hasn't grown its free cash circulation, and except that turns around, future dividend increases should be arduous to Come by using.
I give IBM the facet on valuation, but i'm sticking with my name that Microsoft is a much better dividend inventory. So, this one is a draw.
Winner: Tie.competitive moat
Microsoft continues to bring tenacious consequences for shareholders stemming from its aggressive advantages, including community results, switching prices, and manufacturer. in the fiscal second quarter, income improved 12% year over year, pushed via 48% boom within the traffic cloud business. in the cloud enterprise, Azure grew 76% for the 2nd consecutive quarter as organizations continue partnering with Microsoft for his or her cloud-computing wants, including Kroger, Mastercard, and Walgreens Boots Alliance.
moreover, the software giant's shift to a subscription-based mostly mannequin for workplace continues to supply solid effects. Microsoft now has 33.3 million subscribers to office 365. revenue from productiveness and enterprise approaches (including workplace 365, Dynamics 365, and LinkedIn) grew 13% year over yr within the remaining quarter.
Microsoft has one of the precise manufacturers on the planet, which is because of the the familiarity thousands and thousands of people and corporations savor with home windows and workplace application. The company is tower to leverage that technological expertise and brand awareness in other pleasing areas, together with internet of things, artificial intelligence, and combined truth, besides cloud-computing.
On the different side, IBM has been serving company shoppers for years. massive Blue has huge competencies in consulting organizations throughout many industries to aid them compete more simply.
IBM's main vicissitude is finding boom. while IBM isn't going anywhere, it's additionally now not more likely to grow lots within the next few years. About half of IBM's enterprise is caught in sluggish-starting to be markets enjoy legacy IT features, hardware, and utility features.
youngsters, as that you can behold with Microsoft's synchronous boom, cloud spending is where any the motion is. IT spending is present process a massive to shift to the cloud, which would not play to IBM's strengths. while IBM noticed its cloud enterprise develop 12% ultimate 12 months, that's peanuts compared to Microsoft's extend within the cloud. IBM's cloud market participate is ready 2%, while Microsoft noticed its participate bounce from 8.7% in 2016 to 13.3% in 2017.
Amazon.com and Microsoft are absorbing many of the cloud spending perquisite now. IBM's synchronous acquisition of red Hat will assist, but normal, Microsoft is in a tons enhanced aggressive position.
Winner: Microsoft.Microsoft is the better purchase
IBM could be a fine contrarian guess, mainly if the enterprise begins to expose signs of growth once more. but for now, i would fairly Go with consistency. Microsoft has the financial fortitude, increase, and competitive advantages that fabricate the king of utility a no brainer resolve on.
John Mackey, CEO of total foods Market, an Amazon subsidiary, is a member of The Motley idiot's board of directors. Teresa Kersten, an employee of LinkedIn, a Microsoft subsidiary, is a member of The Motley fool's board of directors. John Ballard owns shares of Amazon and Mastercard. The Motley idiot owns shares of and recommends Amazon, Apple, and Mastercard. The Motley fool owns shares of Microsoft. The Motley idiot is short shares of IBM and has perquisite here alternate options: long January 2020 $a hundred and fifty calls on Apple and short January 2020 $a hundred and fifty five calls on Apple. The Motley idiot has a disclosure policy.
Obviously it is arduous assignment to pick solid certification questions/answers assets concerning review, reputation and validity since individuals earn sham because of picking incorrectly benefit. Killexams.com ensure to serve its customers best to its assets concerning exam dumps update and validity. The vast majority of other's sham report objection customers Come to us for the brain dumps and pass their exams cheerfully and effectively. They never trade off on their review, reputation and trait because killexams review, killexams reputation and killexams customer conviction is vital to us. Uniquely they deal with killexams.com review, killexams.com reputation, killexams.com sham report grievance, killexams.com trust, killexams.com validity, killexams.com report and killexams.com scam. In the event that you behold any unseemly report posted by their rivals with the name killexams sham report grievance web, killexams.com sham report, killexams.com scam, killexams.com dissension or something enjoy this, simply remember there are constantly terrible individuals harming reputation of worthy administrations because of their advantages. There are a remarkable many fulfilled clients that pass their exams utilizing killexams.com brain dumps, killexams PDF questions, killexams hone questions, killexams exam simulator. Visit Killexams.com, their specimen questions and test brain dumps, their exam simulator and you will realize that killexams.com is the best brain dumps site.
P2180-089 exam prep | ST0-057 questions and answers | 1Y0-340 exam questions | ST0-030 mock exam | C9520-422 braindumps | 000-647 exam prep | C2040-985 examcollection | 1Z0-348 study guide | 646-580 bootcamp | 200-125 brain dumps | 920-340 cheat sheets | 000-171 study guide | PEGACPBA71V1 braindumps | GE0-806 sample test | C2180-404 questions and answers | 000-623 test questions | HP0-920 drill test | BCP-810 drill exam | HP2-Z32 free pdf | HP0-T01 dumps |
Never miss these 00M-648 questions you Go for test.
killexams.com offers you undergo its demo adaptation, Test their exam simulator that will empower you to encounter the real test condition. Passing real 00M-648 exam will be substantially less demanding for you. killexams.com allows you 3 months free updates of 00M-648 IBM Rational IT Sales Mastery Test v2 exam questions. Their accreditation group is persistently reachable at back conclude who refreshes the material as and when required.
The best passage to earn success in the IBM 00M-648 exam is that you ought to earn dependable prep material. They guarantee that killexams.com is the most direct pathway towards IBM IBM Rational IT Sales Mastery Test v2 exam. You will be triumphant with plenary surety. You can behold free questions at killexams.com before you purchase the 00M-648 exam products. Their mimicked tests are in different conclusion the identical as the real exam design. The questions and answers collected by the certified professionals. They give you the undergo of taking the real test. 100% assurance to pass the 00M-648 real test.
killexams.com Huge Discount Coupons and Promo Codes are as under;
WC2017 : 60% Discount Coupon for any exams on website
PROF17 : 10% Discount Coupon for Orders greater than $69
DEAL17 : 15% Discount Coupon for Orders greater than $99
DECSPECIAL : 10% Special Discount Coupon for any Orders
In the occasion that would you mutter you are befuddled a passage to pass your IBM 00M-648 Exam? With the assistance of the confirmed killexams.com IBM 00M-648 Testing Engine you'll determine out how to construct your abilties. Most of the understudies launch making undergo of once they find out that they want to expose up in IT certification. Their cerebrum dumps are thorough and to the point. The IBM 00M-648 PDF files fabricate your imaginative and prescient sizeable and assist you a ton in prep of the certification exam.
killexams.com top fee 00M-648 exam simulator is extremely encouraging for their clients for the exam prep. Immensely primary questions, points and definitions are featured in brain dumps pdf. social occasion the information in a unique zone is a real assist and reasons you earn equipped for the IT certification exam interior a quick time frame traverse. The 00M-648 exam offers key focuses. The killexams.com pass4sure dumps keeps the crucial questions or thoughts of the 00M-648 exam
At killexams.com, they give completely surveyed IBM 00M-648 preparing assets which can be the fine to pass 00M-648 exam, and to earn certified with the succor of 00M-648 braindumps. It is a trait election to hasten up your position as an expert in the Information Technology enterprise. They are pleased with their notoriety of supporting individuals pass the 00M-648 exam of their first attempt. Their prosperity quotes inside the preceding years were absolutely exquisite, because of their upbeat clients who're currently prepared to impel their positions in the rapid track. killexams.com is the main conclusion amongst IT professionals, mainly the ones who are hoping to slither up the development tiers faster in their individual associations. IBM is the commercial enterprise pioneer in statistics innovation, and getting certified by them is an ensured approach to be triumphant with IT positions. They allow you to accomplish actually that with their extremely worthy IBM 00M-648 exam prep dumps.
IBM 00M-648 is rare any over the globe, and the commercial enterprise and programming preparations gave by means of them are being grasped through every one of the agencies. They savor helped in riding a massive wide variety of agencies on the beyond any doubt shot manner of achievement. Far reaching studying of IBM gadgets are required to certify as a essential capability, and the professionals showed through them are relatively esteemed in any institutions.
We deliver genuine 00M-648 pdf exam questions and answers braindumps in two preparations. Download PDF and drill Tests. Pass IBM 00M-648 Exam hastily and efficiently. The 00M-648 braindumps PDF sort is accessible for perusing and printing. You can print increasingly and drill by and large. Their pass rate is towering to ninety eight.Nine% and the comparability cost among their 00M-648 syllabus prep manual and actual exam is 90% in light of their seven-year teaching background. accomplish you necessity successs inside the 00M-648 exam in best one try? I am certain now after analyzing for the IBM 00M-648 real exam.
As the simplest thing this is in any passage crucial perquisite here is passing the 00M-648 - IBM Rational IT Sales Mastery Test v2 exam. As any which you require is an immoderate score of IBM 00M-648 exam. The only a unmarried aspect you necessity to accomplish is downloading braindumps of 00M-648 exam assume into account directs now. They will not can succor you down with their unconditional guarantee. The professionals likewise preserve tempo with the most up and coming exam that allows you to provide the extra section of updated materials. One year lax access to savor the capacity to them via the date of purchase. Each applicant might moreover undergo the cost of the 00M-648 exam dumps via killexams.com at a low price. Frequently there may be a markdown for everyone all.
Within the sight of the real exam material of the brain dumps at killexams.com you may with out a lot of a stretch build up your forte. For the IT professionals, it's far crucial to ameliorate their abilties as indicated by means of their position necessity. They fabricate it smooth for their customers to carry certification exam with the succor of killexams.com showed and real exam cloth. For a brilliant future in its realm, their brain dumps are the remarkable desire.
A high-quality dumps composing is an imperative component that makes it simple as a passage to assume IBM certifications. be that as it can, 00M-648 braindumps PDF offers lodging for candidates. The IT affirmation is a sizeable tough project inside the occasion that one doesnt find out legitimate path as genuine asset material. Consequently, we've got actual and updated material for the making plans of certification exam.
It is primary to collect to the manual material at the off risk that one desires in the direction of spare time. As you require bunches of time to search for updated and exact investigation cloth for taking the IT certification exam. In the event which you find that at one region, what may be advanced to this? Its simply killexams.com that has what you require. You can spare time and retain away from bother on the off haphazard that you purchase Adobe IT certification from their website online.
You savor to earn the maximum updated IBM 00M-648 Braindumps with the perquisite answers, which will be installation with the aid of killexams.com experts, allowing the occasion to earn a manage on mastering about their 00M-648 exam course inside the finest, you will not determine 00M-648 outcomes of such best anyplace inside the marketplace. Their IBM 00M-648 drill Dumps are given to candidates at performing a hundred% of their exam. Their IBM 00M-648 exam dumps are maximum current in the market, allowing you to earn geared up for your 00M-648 exam in the proper manner.
killexams.com Huge Discount Coupons and Promo Codes are as underneath;
WC2017 : 60% Discount Coupon for any exams on internet site
PROF17 : 10% Discount Coupon for Orders more than $69
DEAL17 : 15% Discount Coupon for Orders greater than $ninety nine
DECSPECIAL : 10% Special Discount Coupon for any Orders
In the event that you are fervent about successfully completing the IBM 00M-648 exam to launch shopping? killexams.com has driving side created IBM exam addresses with a view to guarantee you pass this 00M-648 exam! killexams.com conveys you the maximum genuine, present and most recent updated 00M-648 exam questions and reachable with a 100% unconditional guarantee. There are many agencies that deliver 00M-648 brain dumps yet the ones are not unique and maximum current ones. Arrangement with killexams.com 00M-648 modern questions is a maximum best approach to pass this certification exam in simple manner.
00M-648 Practice Test | 00M-648 examcollection | 00M-648 VCE | 00M-648 study guide | 00M-648 practice exam | 00M-648 cram
Killexams HP0-P24 exam prep | Killexams 000-561 brain dumps | Killexams 1T6-521 exam questions | Killexams HPE6-A41 brain dumps | Killexams M2065-741 drill questions | Killexams 70-537 pdf download | Killexams HP0-J61 free pdf download | Killexams 4A0-M02 drill Test | Killexams HP2-896 cheat sheets | Killexams 1Y0-731 bootcamp | Killexams EX0-118 study guide | Killexams 210-060 test prep | Killexams Series66 study guide | Killexams 200-310 real questions | Killexams BEC dumps questions | Killexams 000-109 dumps | Killexams HP2-B86 drill test | Killexams HP0-D02 VCE | Killexams 4A0-108 mock exam | Killexams 920-805 real questions |
Killexams LOT-913 pdf download | Killexams HP0-460 dumps | Killexams 000-781 drill Test | Killexams 1K0-001 free pdf | Killexams VCPD610 VCE | Killexams HP2-Z26 exam questions | Killexams 850-001 free pdf | Killexams COG-135 drill exam | Killexams 9A0-327 drill test | Killexams HPE6-A45 braindumps | Killexams 922-104 braindumps | Killexams HP0-A17 drill questions | Killexams HP0-678 cram | Killexams 9A0-055 test prep | Killexams 1Z0-474 dump | Killexams 1Z0-584 real questions | Killexams HP2-Q01 study guide | Killexams 00M-512 real questions | Killexams 1K0-002 brain dumps | Killexams BH0-001 questions and answers |
The International traffic Machines Corporation, better known simply as IBM, is a world leader in IT products and services. It covers IT comprehensively, encompassing enterprise applications, middleware and operating systems, computing systems, storage, cloud computing, and traffic analytics.
IBM became known as substantial Blue, most likely because of the color of its mainframes in the late 1960s. Some of IBM's best-known product brands include B2, Lotus, Tivoli and WebSphere. Today, the company is making its name known with Watson, IBM's cognitive technology.IBM certification program overview
A company as large, widely followed and revered as IBM is bound to savor a well-developed certification program, and indeed it does. The IBM Professional Certification Program boasts almost 300 credentials.
In the past, IBM classified its certifications according to software, hardware, IBM PureSystems, solutions and "other." While individual certifications may still tumble into those common categories, certification classifications savor been revamped to more closely align with the company's product portfolio. IBM currently classifies its certifications across 11 main categories:
Certifications are aimed at IT professionals who implement, advocate or sell IBM products at the Associate, Professional and Advanced Professional (including Expert) tiers. Most certifications can be achieved by passing one or two exams focused on a specific IBM application, system or service, although some expert-level certs require up to five exams.IBM exams and retake policy
IBM certification exams are delivered through Pearson VUE testing centers. An exam may terminal 60 to 150 minutes, include anywhere from 22 to 97 questions, and cost $100 to $200. Exam details vary greatly across certifications, so they provide only high/low information here, and exam prices may change as of the first day of any calendar year. Exam prices moreover vary by geography, so candidates necessity to check prices for their localities.
A candidate who fails an exam the first time may retake it as soon as workable but must wait 30 days before making subsequent attempts. To succor defray costs, IBM occasionally offers a assume It Again promotion in which candidates can retake an exam for free if they fail the first attempt. IBM has moreover been known to tender exams for free at events such as InterConnect 2017. Seating is frequently limited, so interested professionals should check out event offerings and register early.
IBM makes navigating certification smooth with webpages dedicated to its certification process, along with one-stop shopping for test information (exam name and number, associated certification, number of questions, exam length, passing score requirements, plus links to the individual exam page) and easy-to-find exam pricing.
The following sections provide a high-level view of IBM certifications in each of the main categories.IBM Analytics
Featuring more than 100 certifications, IBM Analytics is IBM's largest certification category, reflecting the growing industry consume of analytics and IBM's leadership in this area. Analytics certifications are designed for professionals working with IBM solutions for performance management and traffic intelligence.
IBM offers Analytics certifications in four areas: Cloud Content Services, Cognos Analytics, Collaboration Solutions and social Business, and Platform Analytics. While there is some overlap among products, each concentration zone features credentials in different portions of the IBM Analytics product portfolio:
IBM offers Analytics credentials from entry smooth to expert.IBM Cloud
Formerly IBM Cloud and Mobility, the IBM Cloud certification portfolio has grown exponentially and now offers more than 70 certifications, making it IBM's second largest certification portfolio. IBM Cloud credentials focus on six primary areas:
This portfolio features credentials for developers, administrators and solution architects.IBM Cognitive Solutions
IBM Cognitive Solutions certifications focus mainly on the Cognos, OpenPages and Algo One products. Where Cognos is geared toward traffic intelligence, analytics and financial strategy management, OpenPages facilitates governance, risk and compliance management. Algo One is a instrument used for analyzing risk factors and models. IBM's Cognitive Solutions certifications are available at the administrator, associate and advanced developer, solution designer, and specialist levels.IBM Commerce
IBM Commerce certifications are any about the customer, and how professionals working with IBM technology can succor the customer conduct and grow its business. Commerce certs Come in three flavors: engaging the customer, colleague and supplier relationships, and digital commerce. These certs cover a wide swath of credential roles, including traffic analysts, solution designers, system administrators, application developers, and deployment and implementation professionals.
The Customer rendezvous category features credentials that focus on maximizing the customer product undergo for WebSphere Commerce, Digital Analytics, Tealeaf, Marketing Operations, Sterling (Configuration, Order Management), drive and Interact.
Partner and Supplier rendezvous certifications focus on professionals managing colleague and supplier relationships. Products featured include Sterling Connect Direct, WebSphere Transformation Extender, Emptoris compress Management and Sterling B2B Integrator.
Digital undergo credentials target professionals charged with enhancing the customer's digital undergo and focus on WebSphere Portal, Web Content Manager, Digital Experience, Forms, Forms undergo Builder and Web undergo Factory.IBM Global Financing
IBM offers a unique Global Financing credential, the IBM Global Financing Sales Master Specialist Professional certification. A unique exam is required to earn the credential.IBM Global Technology Services
IBM Global Technology Services is promoted as the IBM group that builds and manages "the backbone that powers the era of enterprise hybrid IT." Simply put, GTS is any about services (both outsourced and managed services) for Watson, hardware, software and common technical support.
IBM offers a unique cert in this category: the IBM Certified Specialist – IBM U.S. Technical advocate Services V2. This certification is only available in the U.S. and is geared toward traffic partners who provide smooth 1 or 2 technical support. Candidates must pass a unique exam to earn the credential.IBM Security
In today's cognitive era, IT infrastructure security is essential to ensuing IT services are not only predictable but compliant and secure as well. An individual with an IBM Security certification has proven skills in designing, implementing, configuring, testing and/or supporting specific IBM security products. Many IBM Security certifications target professionals who process and resolve specialized data geared toward law enforcement, government agencies and municipalities (utility-related).
IBM security products include IBM Security Guardium, Security QRadar, i2 Analysts Notebook, Security SiteProtector, Endpoint Manager, MobileFirst Protect and many others. The IBM Security certification portfolio offers IT professionals 32 different options to hone and validate their security skills.
Depending on the certification, available credentials include administrator and associate administrator, analyst and associate analyst, associate, deployment professional, integration professional, solution advisor, security intelligence, and specialist. Deployment professional certs fabricate up approximately one-third of the available security credentials (11 total).IBM Systems
IBM currently offers 29 different IBM Systems certifications aimed at users, advanced users, implementers and sellers. IBM Systems certs tumble into five categories:
You may remember the now-famous bout where IBM's Watson supercomputer won the "Jeopardy" game exhibit challenge, ushering in a modern era in cognitive computing, substantial data and analytics. Since that time, IBM kick-started the IBM Watson Group with a sound $1 billion in startup funding. Today, IBM Watson is rapidly becoming an industry leader for technology platforms that leverage the power of natural language and machine learning.
Eighteen IBM Watson certs are available. Seven certifications focus on Maximo Asset Management solutions, while the remaining certs are divided between TRIRIGA, Collaborative Lifecycle Management, Rhapsody, Predictive Maintenance and Quality, and Rational. Available credentials include associate, consultant, solutions (specialist, expert and advisor), deployment (infrastructure and advanced) and application developer.IBM Watson Health
A brainchild of The Watson Group, Watson Health is one of the newest rising stars at IBM. Watson Health boasts numerous partnerships with healthcare industry leaders.
There are currently two Watson Health certs available: IBM Certified Application Developer – Curam V604 and IBM Certified Associate traffic Process Analyst – Curam V605. The Certified Application Developer – Curam is an intermediate credential that targets Java professionals who moreover work as Curam developers. The Associate traffic Process Analyst – Curam is an entry-level credential for testers, traffic analysts or consultants seeking to establish foundation-level Curam skills or implement Curam projects. A unique test is required for each certification. Note: IBM traffic colleague candidates who've purchased a Value Package qualify for IBM's You Pass, They Pay (YPWP) Program. Under the YPWP program, candidates are reimbursed for exams and some preparatory courses.IBM Watson: Internet of Things
The internet of things, or IoT, is certainly changing the passage they connect, interact and conduct business. The IBM Watson: Internet of Things portfolio is a modern addition to the IBM family. enjoy IBM Watson certs, the IBM IoT certs focus primarily on Maximo Asset Management, Rational and TRIRIGA products. Credentials include specialists, associates, deployment professionals and more.Related jobs, careers and training resources
You'll find IBM-certified professionals employed in a variety of job roles that span any industry sectors. A simple job search for "IBM professionals" on Simply Hired turned up more than 40,000 job postings. For example, they establish these postings:
Other common job roles included developers, traffic analysts, technical solution engineers, platform advocate engineers and integration leads. Career choices are limited only by your personal interests and aspirations.
IBM maintains a list of training resources for each exam on the individual exam webpage. Here, candidates will find test objectives, sample exams and assessment tests, as well as links to more formal training and other resources. Additional training materials, including books and e-books, may be purchased from the IBM Professional Certification Marketplace. On the IBM Training and Skills webpage, candidates will find links to blogs, articles, learning opportunities, events, Redbooks and PartnerWorld.
Miscellaneous SoftwarePress Release Summary:
Based on WindowTester technology, WindowTester(TM) Pro v2.0 Eclipse-based software development instrument streamlines testing of Java client applications, facilitating creation of consistent and reliable user interfaces. Supporting automated GUI testing for both swing and SWT frameworks, software is compatible with Microsoft Windows and Linux (GTK) and installs into any Eclipse-based development environment and automated build systems enjoy Ant, Cruise Control, or Maven.Original Press Release: Instantiations WindowTester Pro Automates Java GUI Testing
Eclipse-based instrument virtually eliminates hand-coding GUI tests for favorite Java swing and SWT frameworks
SANTA CLARA, Calif., March 6 / -- EclipseCon 2007 -- Instantiations, Inc., a leading provider of software trait and productivity solutions, today announced the release of WindowTester(TM) Pro 2.0. An Eclipse-based software development product, the modern product streamlines the testing of Java client applications making it easier to create richer, more consistent and reliable user interfaces. The modern product is based on the market-proven WindowTester technology contained in Instantiations' RCP Developer.
As software development cycles shrink from months to weeks, automated, reliable GUI testing becomes increasingly necessary to meet customer expectations and software trait goals. Manual GUI testing is time-consuming, labor-intensive and expensive and is usually left until the conclude of the development process. Manual testing depends on individuals following a set of tangled directions, making the results discordant and often unrepeatable. Finding software "bugs" late in the development cycle is no longer a choice. It delays product rollout and increases the cost of enterprise and shrink- wrapped software products.
"Since they started using WindowTester, tests that took 2-3 weeks to write previously can now be done in 2-3 days," said Steve Tocco, director of trait assurance Workshop unit at BEA Systems.
"Developers resist GUI testing because it's complex, time-consuming and diffuses their focus on product development," said Dan Rubel, chief technology officer, Instantiations, Inc. "WindowTester reduces both the testing complexity and time needed. And it frees them to build trait applications because it automates recording, test generation, code coverage and playback of GUI to application interactions rather than requiring time-consuming, hand- crafted and high-maintenance test code."
"In terms of their investment in the WindowTester tool, they believe the cost of the licensing is greatly worth the enhancement and efficiency gained so far," said Bill Roth, vice president Workshop unit, BEA Systems.
The WindowTester approach is based on the JUnit benchmark so it takes advantage of the aboriginal Eclipse test framework. By offering greater flexibility in test development, maintenance and access to Java code, WindowTester is superior to existing alternatives, such as Abbot or the Eclipse Test and Performance Tools Platform (TPTP) that only advocate a unique Java platform. WindowTester Pro supports Microsoft Windows, Linux (GTK) and installs easily into any Eclipse-based development environment. It's equally smooth to integrate with automated build systems enjoy Ant, Cruise Control or Maven.
"WindowTester Pro operates similarly to the window testing role in RCP Developer that their customers are intimate with," said Rubel. "However, WindowTester Pro supports automated GUI testing for both favorite Java GUI frameworks, swing and SWT, and promises to be a more complete Eclipse GUI testing environment for enterprises."
Price and Availability
WindowTester Pro 2.0 is available immediately and in several configurations to meet different customer needs. For users who prefer more flexibility or a lower initial investment, the company offers a per developer subscription cost of $319 (USD) a year for the WindowTester Tools Library(TM). The yearly subscription provides access to any the product tools available in the library -- including WindowTester Pro, WindowTester SWT and WindowTester swing -- as well as upgrades and technical support.
For users who prefer a benchmark software license agreement, Instantiations offers WindowTester Pro separately for $799 (USD) per seat license. WindowTester SWT and WindowTester swing are each available separately for a $499 (USD) per seat license. Annual advocate for these products costs 25 percent of the first year's price.
For additional information or pricing on this product, gladden contact their sales department at (800) 808-3737 or by email at firstname.lastname@example.org. The products and free 14-day evaluations may be downloaded immediately from the company's web site at http://instantiations.com/windowtester/.
Instantiations, Inc. provides leading-edge software products, services and technologies for Eclipse, Java and Smalltalk. The company offers high-value, high-ROI professional development environments and engineering consulting services that focus on improving software trait and developer productivity. Instantiations is a member of the Eclipse Foundation and offers a line of products for Eclipse, IBM Rational and WebSphere Studio, and MyEclipse. Based in Portland, Ore., Instantiations was founded in 1997 by a team of internationally recognized pioneers in component software technology. For more information, visit www.instantiations.com/. Or convoke the company at (800) 808-3737.
Source: Instantiations, Inc.
CONTACT: sequel Johnson of Instantiations, Inc., +1-503-598-4909, email@example.com;
Web site: http://www.instantiations.com/Related Thomas Industry Update
Typically, a drug repurposing strategy consists of three steps before taking the candidate drug further through the development pipeline: identification of a candidate molecule for a given indication (hypothesis generation); mechanistic assessment of the drug sequel in preclinical models; and evaluation of efficacy in phase II clinical trials (assuming there is adequate safety data from phase I studies undertaken as section of the original indication). Of these three steps, step 1 — the identification of the perquisite drug for an indication of interest with a towering smooth of assurance — is critical, and this is where modern approaches for hypothesis generation could be most useful. These systematic approaches can be subdivided into computational approaches and experimental approaches (Fig. 1), both of which are increasingly being used synergistically. Drug repurposing based on clinical data is encompassed within these two broad areas.Figure 1: Approaches used in drug repurposing.
Various computational approaches can be used individually or in combination to systematically analyse different types of large-scale data to obtain meaningful interpretations for repurposing hypotheses. Challenges for such analyses are discussed in Box 5. Experimental approaches can moreover be used to identify repurposing opportunities. EHR, electronic health record.Computational approaches
Computational approaches are largely data-driven; they involve systematic analysis of data of any character (such as gene expression, chemical structure, genotype or proteomic data or electronic health records (EHRs)), which can then lead to the formulation of repurposing hypotheses11 (Fig. 1). The most commonly used computational approaches, together with drug repurposing examples, are discussed below.
Signature matching. Signature matching is based on the comparison of the unique characteristics or 'signature' of a drug against that of another drug, disease or clinical phenotype12,13. The signature of a drug could be derived from three common types of data: transcriptomic (RNA), proteomic or metabolomic data; chemical structures; or adverse event profiles, which they debate in rotate below.
Matching transcriptomic signatures can be used to fabricate drug–disease comparisons (estimating drug–disease similarity)14 and drug–drug comparisons (drug–drug similarity)15. In the first case, the transcriptomic signature of a particular drug is derived by comparing the gene expression profile of biological material, such as a cell or a tissue, before and after treatment with the drug; the resultant differential gene expression signature (the molecular signature of the drug) is then compared with a disease-associated expression profile that has been similarly obtained through differential expression analysis of disease versus sound conditions. The extent of negative correlation between the gene expression signature of the drug and that of the disease (that is, the genes upregulated in the disease are downregulated with the drug and vice versa) would then allow inference of whether the drug may savor a potential sequel on the disease16,17 (see the case study of topiramate in Box 2). This computational approach relies on the signature reversion principle (SRP), where it is assumed that if a drug can transpose the expression pattern of a given set of genes that are a hallmark for a particular disease phenotype (that is, the drug signature will be closer to that obtained for the sound state), then that drug might be able to revert the disease phenotype itself. Despite this principle being quite simplistic, it has been demonstrated for metabolic disorders18 and successfully exploited to identify novel drug repositioning opportunities in a wide purview of therapeutic areas19,20,21,22,23,24. The SRP has moreover been successfully employed to identify drugs that could be repositioned as chemo-sensitizers based on anticancer drug-resistance signatures25.Box 2: Drug–disease similarity approach to identify topiramate in IBD
Dudley and colleagues16 compared the gene expression signature of inflammatory bowel disease (IBD) derived from publicly available data obtained from the National focus for Biotechnology Information (NCBI) Gene Expression Omnibus with the gene expression profile of 164 drugs obtained from the Connectivity Map (cMap). Therapeutic predictions for drug–disease pairs were derived based on the extent of negative correlation between the gene expression signature of the drug and that of the disease. One of the strongest therapeutic predictions they obtained for IBD was the corticosteroid prednisolone, which is widely used to reduce inflammation associated with IBD. Another drug that showed a stronger correlation with both Crohn's disease and ulcerative colitis — two primary clinical manifestations of IBD — was topiramate, an antiepileptic drug with GABA agonistic activity.
The authors validated the potential efficacy of topiramate in IBD using a trinitrobenzenesulfonic acid-induced rat model of IBD, in which it significantly reduced diarrhoea, visual manifestations of colitis on endoscopy and microscopic manifestations of disease on colonic biopsy. Functional enrichment analysis indicated that genes involved with gastrointestinal disease, inflammatory response and other immune-related functions were divergently expressed between the drug-affected and disease-affected conditions, further highlighting some of the potential mechanisms by which topiramate may act in IBD. However, a recent retrospective cohort study using administrative claims data from the MarketScan databases in the US failed to exhibit a profitable sequel of topiramate in IBD110. Nevertheless, it is thoughtprovoking to note that GABA has been recently suggested to play a potential role in gastrointestinal inflammation111. Thus, an appropriately designed and powered randomized clinical affliction would be required to definitively reply the question of whether topiramate can be used therapeutically in IBD.
Drug–drug similarity approaches train to identify shared mechanisms of action of otherwise dissimilar drugs (drugs that belong to different classes or that are structurally dissimilar). This principle is called guilt by association26 and can aid the identification of alternative targets of existing drugs and uncover potential off-target effects that can be investigated for clinical applications12. A shared transcriptomic signature between two drugs could therefore imply that they moreover participate a therapeutic application, regardless of the similarity or dissimilarity in their chemical structures27 (see the case study of fasudil in Box 3). This principle has proved effective even when comparing transcriptional signatures that are reflective of a secondary mode of action, which could be shared, for example, by a group of pharmacologically diverse mild correctors of a given disease phenotype28,29.Box 3: Drug–drug similarity approach to identify the potential consume of fasudil in amyotrophic lateral sclerosis
Iorio and colleagues27,112 used the 'guilt by association' principle to construct a drug network using publicly available transcriptomic profiles of drugs, which allowed them to identify drugs with a similar transcriptional signature and therefore a perceived similar mechanism of action. Using gene expression profiles of each drug across multiple treatments on different cell lines and/or at different dosages obtained from the Connectivity Map (cMap), they computed a representative transcriptional response for each drug. A drug network was then constructed in which two drugs were connected to each other if their optimal transcriptional responses were similar according to a similarity measure developed by the authors (called drug distance). This resulted in a drug network of 1,302 nodes (drugs) and 41,047 edges (indicating similarities between pairs of drugs) purely based on transcriptomic profiles of drugs within this network consisting of drugs with a similar transcriptional signature and therefore a perceived similar mechanism of action.
Using this network, the authors correctly predicted the previously known mechanism of action of nine anticancer compounds, thereby validating this predictive model. Importantly, they moreover predicted previously unknown mechanisms for drugs such as fasudil, a Rho-kinase (ROCK) inhibitor, based on its proximity to known autophagy enhancers such as 2-deoxy-d-glucose and tamoxifen, and validated their prediction using an in vitro fibroblast model112. Autophagy plays a key role in the pathogenesis of amyotrophic lateral sclerosis (ALS)113, a neurodegenerative disease with no cure. Preclinical studies in animal models of ALS showed that fasudil can extend motor neuron survival in transgenic mice expressing mutant superoxide dismutase 1 (SOD1), the causal gene for congenital forms of ALS114. The profitable effects of fasudil in preclinical models of ALS were moreover confirmed in other preclinical studies115,116. This has now led to an open-label, single-centre clinical affliction in China to investigate the efficacy and safety of fasudil in ALS (NCT01935518).
Both drug–disease and drug–drug similarity approaches involve matching of transcriptomic signatures and therefore depend heavily on publicly accessible gene expression data. The Connectivity Map (cMap), which was established in 2006 by the Broad Institute, consists of gene expression profiles generated by dosing of more than 1,300 compounds in a number of cell lines30 (Connectivity Map; behold Related links). cMap information can be considered as a proxy phenotypic screen for a great number of compounds and has been successfully used to fabricate drug repurposing predictions for a number of disease conditions. The third instalment of the cMap data repository (cMap 3.0) is now available within the US National Institutes of Health (NIH) Library of Integrated Network-based Cellular Signatures (LINCS; behold Related links). It encompasses transcriptional signatures generated with tens of thousands of compounds upon treatment of hundreds of human cell lines. This gargantuan resource can be used along with other primary public repositories of transcriptomic data, such as the Gene Expression Omnibus (see Related links) and Array Express (see Related links), which contain raw gene expression data from hundreds of disease conditions in humans and animal models. Manual curation or dedicated computational tools31 can then be used to interrogate these disease signatures in association with the cMap data to identify novel drug–disease connections and potential drug repositioning opportunities32,33.
The second character of signature matching used in drug repurposing is based on chemical structures and their relationship to biological activity34; comparing the chemical signature of one drug with that of another drug to behold whether there are chemical similarities could hint shared biological activity. The process involves selecting a set of chemical features for each drug and then constructing networks based on the shared chemical features. This is exemplified by the statistics-based cheminformatics approach undertaken by Keiser and colleagues12 to predict modern targets for 878 US Food and Drug Administration (FDA)-approved small-molecule drugs and 2,787 pharmaceutical compounds. Using a similarity ensemble approach (SEA) to evaluate the 2D structural similarity of each drug to each target's ligand set, they were able to identify 23 modern drug–target associations.
Chemical similarity approaches savor their pitfalls: errors in chemical structures as well as physiological effects that exist beyond the structural relationship (for example, a metabolite of the original drug with a modified structure could be the dynamic molecule) could circumscribe the consume of this approach in drug repurposing14.
Finally, every drug has a relatively unique adverse sequel profile that could be used as a proxy for its phenotype. Matching the adverse sequel signature of drugs is based on the hypothesis that two drugs that judgement the identical adverse effects may be acting on a shared target or protein or on the identical pathway14. It is moreover workable that the adverse sequel phenotype of a particular drug may resemble that of a disease; this would hint shared pathways and physiology by both the drug and the disease. Peer Bork's group used the adverse sequel similarity approach to identify novel drug–target relationships for 746 approved drugs35. They used the Unified Medical Language System (UMLS) ontology for medical symptoms and extracted pertinent adverse sequel profiles from drug package inserts, weighted them based on frequency and scored these drugs based on adverse sequel similarities. This approach not only confirmed previously known drug–drug pairs that shared the identical protein target but moreover identified modern shared targets for 754 drug pairs. A different approach was used by Yang and Agrawal to match adverse drug effects with disease36; they combined adverse sequel information derived from drug labels with drug–disease relationships obtained from the PharmGKB database and were able to predict repurposing indications for 145 diseases.
Although this is a logical approach to consume for identifying repurposing opportunities, the vicissitude in mining adverse sequel information from drug package inserts and the want of well-defined adverse sequel profiles and causality assessments for a number of drugs14 could circumscribe its use. However, artificial intelligence technologies that can undertake text mining and natural language processing portray potential future opportunities to overcome these limitations.
Computational molecular docking. Molecular docking is a structure-based computational strategy to predict binding site complementarity between the ligand (for example, a drug) and the target (for example, a receptor)37. If there is prior knowledge of a receptor target involved in a disease, then multiple drugs could be interrogated against that particular target (conventional docking: one target and multiple ligands). Conversely, drug libraries could be explored against an array of target receptors (inverse docking: several targets and one ligand) to identify novel interactions that can be taken forward for repurposing. Using high-throughput computational docking, Dakshanamurthy and colleagues38 performed molecular suitable computations on 3,671 FDA-approved drugs across 2,335 human protein crystal structures. They discovered that mebendazole, an anti-parasitic drug, has the structural potential to inhibit vascular endothelial growth factor receptor 2 (VEGFR2), a mediator of angiogenesis; this was moreover confirmed experimentally.
However, there are several issues with the consume of molecular docking for drug repurposing. First, 3D structures for some protein targets of interest may not be available, particularly because drug targets are often membrane proteins, such as G protein-coupled receptors (GPCRs), although substantial progress has recently been made in GPCR crystallography39. Second, there is a want of well-curated macromolecular target databases that provide accurate structural information40, although this is getting better41. Finally, the utility of docking algorithms to predict the affinity of binding has been questioned42 and, while it is improving, there can be differences between different software packages, and some limitations in predictability (for instance, mode of binding and entropic effects) still remain43.
Genome-wide association studies. There has been a great extend in the number of genome-wide association studies (GWAS) conducted over the past 10 years following advances made in genotyping technology, the completion of the Human Genome Project and dwindling genotyping costs. GWAS train to identify genetic variants associated with common diseases and thereby provide insights into the biology of diseases; the data obtained may moreover succor identify novel targets, some of which could be shared between diseases treated by drugs and disease phenotypes studied by GWAS and thereby lead to repositioning of drugs44. Sanseau and colleagues44 refined the catalogue of published GWAS traits from the US National Human Genome Research Institute (NHGRI) and establish that genes that were associated with a disease trait were more likely to code for proteins that are 'druggable' or 'biopharmable' than the leisure of the genome, with the GWAS gene set enriched by 2.7-fold in targets being pursued by the pharmaceutical industry. They moreover establish 92 individual genes with a GWAS trait that was different from the original drug indication, suggesting that it is workable to evaluate drugs that target the products of these 92 genes for a modern disease indication (see the case study for denosumab in Box 4). Another recent study by Grover and colleagues45 used a bioinformatics approach to match gene targets identified for coronary artery disease with drug information obtained by integration of three different drug–target databases (DrugBank, Therapeutic Target Database and PharmGKB) to identify potential repositioning opportunities.Box 4: consume of GWAS-identified targets for potential repurposing of denosumab in Crohn's disease
Denosumab (Prolia, Amgen), which is marketed for the treatment of postmenopausal women at towering risk of fracture with osteoporosis, is an antibody that targets tumour necrosis factor ligand superfamily member 11 (TNFSF11), moreover known as RANKL. TNFSF11 has moreover been shown to be activated in Crohn's disease, in which a substantial symmetry of patients savor osteopenia and osteoporosis117. Moreover, a TNFSF11 genetic variant (rs2062305) has moreover been associated with Crohn's disease by genome-wide association studies (GWAS)118.
This prompted Sanseau and colleagues44 to speculate about a potential role for denosumab in Crohn's disease. Using human B-lymphoblastoid cells and osteoblasts, they establish that the Crohn's disease-associated TNFSF11 variant was associated with the differential expression of TNFSF11 and was able to account for population variation in TNFSF11 expression in both cell types representing discrete cellular lineages pertinent for both inflammatory and bone disease. This provided further advocate to postulate a causal link between TNFSF11 and Crohn's disease and the potential for repurposing denosumab in Crohn's disease. A recent preclinical study explored the efficacy of daily denosumab injection in a mouse model of colitis induced by dinitrobenzenesulfonic acid119. Denosumab was establish to abate pro-inflammatory cytokines and modify the gut microbiota diversity in this animal model, further supporting its potential consume in treating manifestations of inflammatory bowel disease. The identical investigators are currently conducting an open-label phase I/II affliction of denosumab in patients with dynamic Crohn's disease (NCT02321280). The study is due for completion in July 2019.
However, there are challenges in the consume of GWAS information for drug repositioning, and its utility at present is unclear. GWAS signals in gene-rich loci with tenacious linkage disequilibrium may fabricate identification of causal gene and/or gene variants difficult44. Another issue is the want of information on the direction of sequel of the gene variant; functional studies will necessity to be conducted to ascertain this before deciding whether an activator or a suppressor is required to control the disease44. GWAS data accomplish not provide minute pathophysiological information, and hence, rational consume of GWAS data is advocated before predicting repurposing targets46. It should moreover be famed that the current understanding of the human genome is not final and there may be many more modern genes discovered47.
Pathway or network mapping. Pathway-based or network-based approaches savor been widely used to identify drugs or drug targets that may savor potential in repurposing48. As discussed above, even though some of the potential targets establish by GWAS or other means may fabricate themselves directly amenable as drug targets, quite often, these genes may not be example druggable targets. In such circumstances, a pathway-based strategy may provide information on genes that are either upstream or downstream of the GWAS-associated target and could be exploited for repurposing opportunities49. Network analysis involves constructing drug or disease networks based on gene expression patterns, disease pathology, protein interactions or GWAS data in order to aid identification of repurposing candidates. Some of the signature matching studies discussed earlier moreover fabricate consume of the network analysis approach27,50. A recent study by Greene and colleagues51 combined genetic variant information arising from GWAS with tissue-specific functional interaction networks using a technique termed network-wide association study (NetWAS) to identify disease–gene associations much more accurately than GWAS alone. By applying this strategy to hypertension and by querying the resultant data against drug–target data from DrugBank, they observed that targets of antihypertensive drugs were enriched to a greater extent among the top genes from NetWAS than with GWAS. Pathway analysis of gene expression data sets from studies involving a wide purview of respiratory viruses in human host infection models identified 67 common biological pathways that may be primary in respiratory viral infections48. Interrogation of these pathways against the DrugBank database identified several drugs with a potential sequel against host-viral targets. These included pranlukast, a leukotriene receptor 1 antagonist used in asthma, and amrinone, a phosphodiesterase inhibitor used in the treatment of congestive heart failure. It has been postulated that both of these drugs could be useful in treating viral infections owing to their potential ability to alter the immune response.
Retrospective clinical analysis: consume of electronic health records. The best instance of retrospective clinical analysis leading to repurposing (or rescue if the drug had otherwise failed for its primary indication) of a candidate molecule is sildenafil1. Other examples for repurposing opportunities arising from retrospective clinical and/or pharmacological analyses include aspirin in colorectal cancer (the US Preventive Services chore obligate released draft recommendations in September 2015 regarding the consume of aspirin to succor forestall cardiovascular disease and colorectal cancer52), raloxifene in breast cancer (Evista; approved by the FDA to reduce the risk of hormone-receptor-positive breast cancer in postmenopausal women who savor not been diagnosed but are at higher-than-average risk of disease) and propranolol in osteoporosis53. However, the above cited examples did not arise as a result of a systematic analysis of clinical data. A systematic approach for analysing clinical data is now increasingly suggested for identifying drug repurposing opportunities54.
Retrospective clinical data can be obtained from various sources, including EHRs, post-marketing surveillance data and clinical affliction data. EHRs contain an gargantuan amount of data on patient outcomes, both structured and unstructured. The diagnostic and pathophysiological data, including the results of laboratory tests as well as drug prescribing data, are more structured; however, EHRs moreover contain considerable amounts of unstructured information, such as clinical descriptions of patient symptoms and signs (which are primary in defining disease phenotype) and imaging data. This wealth of data present in EHRs could be used as a source for identifying signals for drug repurposing11; in addition, the gargantuan amount of EHR data moreover provides towering statistical power55. Paik and colleagues55 extracted clinical signatures from over 13 years of EHRs from a tertiary hospital, including >9.4 million laboratory tests from half a million patients, in addition to diverse genomics signatures to identify over 17,000 known drug–disease associations; this approach led to the identification of terbutaline sulfate, an anti-asthmatic, as a promising candidate for the treatment of amyotrophic lateral sclerosis (ALS).
The UK Clinical drill Research Datalink (CPRD), the Yellow Card scheme of the Medicines and Healthcare Products Regulatory Agency (MHRA), EudraVigilance (a European database of suspected adverse drug reaction reports managed by the European Medicines Agency (EMA)), the FDA Adverse Event Reporting System (FAERS) and the World Health Organization (WHO) global database for adverse drug reactions (VigiBase) any contain valuable patient, disease and drug data that could serve as primary sources for drug repurposing analyses. However, remarkable challenges still lie ahead in accessing and using EHR data, including ethical and legal obstacles that circumscribe access to the data and vicissitude in extracting the unstructured information present in these databases. building more research capability into EHR databases could succor ameliorate their utility for various downstream opportunities such as drug repurposing. Natural language processing and machine-learning techniques could moreover prove valuable.
Post-marketing surveillance data and clinical affliction data are two other primary substantial data sources, but access may be limited for commercial or confidentiality reasons. However, there is increasing realization that opening up access to such wealth of information can aid further drug development research. In October 2016, the EMA started providing direct public access to clinical affliction data submitted by pharmaceutical companies and has published reports on six different drugs to date (European Medicines Agency Clinical Data; behold Related links). The data can be used for independent reanalysis by academics and researchers and may bespeak drug repurposing leads.
Novel sources of data for drug repurposing. Immortalized human cancer cell lines (CCLs) savor been used in high-throughput drug screens against hundreds of compounds (both approved and experimental) to test their sequel on cell viability56,57. In a number of studies, the pharmacological data sets resulting from these screens savor been paired with comprehensive genomic characterization of the probed CCLs, thereby allowing identification of interactions between molecular features of the cell and drug response (pharmacogenomic interactions)58,59,60,61. Mining such publicly available data sets containing paired genomic and pharmacological data on great panels of CCLs has been suggested as a novel resource for identifying drug repositioning opportunities. CCLs are of course imperfect models: they might savor acquired molecular alterations providing selective advantages for in vitro culture and are often biased towards certain molecular subtypes. However, despite these limitations, studies savor shown how identifying pharmacogenomic interactions recapitulate therapeutic genomic markers already in clinical use, with a strength of association that is comparable to that observed in the clinic58,59,60,61.
More recently, CCL studies savor moreover been integrated with the genomic characterization of great cohorts of primary tumours to prioritize the identified pharmacogenomic interactions on the basis of the clinical prevalence of the involved genomic alterations60. Strikingly, many of the novel identified pharmacogenomic interactions were specific to cancers of a given tissue character and involved drugs that are already in clinical consume for other diseases or for cancers of other tissue types. The data arising from these types of study could be used to identify drug repurposing opportunities. Furthermore, this novel investigative avenue would tender an additional advantage: identification of the genomic alteration involved in a pharmacogenomic interaction with a repurposable drug would allow it to be prescribed to a very well-defined subpopulation of patients, thus advancing personalized cancer therapy.
EHR-linked great DNA biobanks could be another frontier in accelerating drug repurposing research62. GlaxoSmithKline utilized China Kadoorie Biobank (CKB)63, a prospective cohort of half a million individuals, to examine the role of PLA2G7 gene variants in major vascular disease64 following the failure of two consecutive phase III trials for darapladib (an inhibitor of the PLA2G7 gene product Lp-PLA2) in coronary heart disease and acute coronary syndrome65,66. PLA2G7 gene variants did not exhibit any association with major vascular disease, providing further advocate for findings from the phase III trials. Although a biobank resource was used to authenticate the want of efficacy of a drug in this case, the identical approach could be used to authenticate gene targets for drug repurposing. Tapping into resources offered by great biobanks that are linked to EHRs, such as the UK Biobank, may be a valuable approach for assessing potential drug targets.
Advances in sequencing technologies are enabling the collection of great quantities of comprehensive genomic data from many individuals that could be useful for drug repurposing. For example, the HiSeq X Ten system developed by Illumina (San Diego, California) is able to sequence more than 18,000 entire human genomes per year (the volume of which will be 3.6 petabytes or 3,600 terabytes)67. Large-scale projects harnessing such technologies include the 100,000 genome project launched in the UK in 2014 (Ref.68), which has a focus on rare diseases and cancer, and the any of Us research programme in the United States (formerly called the Precision Medicine Initiative69), which will genotype 1 million individuals. This is in addition to various initiatives by other countries (for example, China has announced its own precision medicine genome sequencing initiative, with an estimated cost of $9.2 billion70) and private consortia (for example, AstraZeneca's genome sequencing initiative in drug discovery (see Related links) in collaboration with Human Longevity in the US, the Wellcome faith Sanger Institute in the UK and The Institute for Molecular Medicine in Finland, which will involve 2 million individuals). Data from these projects could provide modern insights into the genetic basis of disease and bespeak therapeutic targets for both modern drug discovery and opportunities for drug repurposing, as with GWAS discussed above. This could be particularly valuable for rare diseases (Box 1) if causative genetic variations are identified in proteins for which potential candidates for drug repurposing are already available. For example, the phosphatidylinositol 3-kinase α-selective inhibitor, alpelisib (BYL719), which has been developed for the treatment of PIK3CA-altered tumours71, was recently shown to be effective in a mouse model of, and in 19 human subjects with, PIK3CA-related overgrowth syndromes (PROS) based on the fact that affected patients savor somatic, mosaic gain-of-function mutations in the PIK3CA gene72.
Nevertheless, it should be famed that the nature of the substantial data from such projects and from the consume of other high-throughput technologies poses considerable challenges for analysis and effective application, both in modern drug discovery and drug repositioning (Box 5).Box 5: The challenges of substantial data
Advances in technology such as next-generation sequencing and continuously reducing costs denote that researchers can generate great quantities of experimental data; these include data generated by high-throughput DNA and RNA sequencing, mass spectrometry, metabolomics and transcriptomic data, phenotyping and many more. Added to this are great amounts of clinical data that are increasingly becoming available from electronic health records (EHRs), clinical trials and biobanks. Such data are often referred to as substantial data — data sets that are so great or tangled that traditional data processing methods are inadequate120.
Big data are primary for improving their understanding of disease and developing strategies for disease prevention and treatment. However, they are facing an increasing gap between their ability to generate substantial biomedical data and their ability to integrate, analyse and interpret the data67. This is further compounded by their ability to generate great amounts of data in a minimal amount of time. Another problem with substantial data is that they are disparate and heterogeneous, which makes data integration extremely difficult120,121. Integrating multiple types of data has proved to extend the power of analysis122, and there are already some examples in drug repurposing where this strategy has been utilized at a limited scale123,124. However, much of the data generated are unstructured, such as imaging and structural data, and this adds another layer of complexity. There is an exigent necessity for technology solutions that can combine heterogeneous data sets and integrate, analyse and interpret them.
Finally, another bottleneck lies in accessing various types of data120,121. Although the publicly available databases for transcriptomic data are well known and contain standardized data, such databases are rare for other types of data, such as clinical affliction data and structural, in vitro or imaging data. For example, access to clinical affliction data is limited at the moment, and even if access is obtained, this may involve mining of gargantuan amounts of data (for example, the clinical affliction data published by the European Medicines Agency for only two drugs, carfilzomib and lesinurad, constitutes ~260,000 pages of information in over 100 clinical reports). Therefore, it is primary to savor publicly accessible repositories that hold data in a standardized format and savor the necessary tools to mine such data.
Finally, online self-reported patient data savor been suggested as another modern potential source for drug repurposing11,73. One instance is self-reported data on the usage of lithium carbonate by patients with ALS, which were used to derive useful conclusions about the efficacy of usage73. Even though no sequel of lithium on disease progression was identified, the approach suggests that data reported by patients over the Internet may be useful for accelerating clinical discovery and evaluating the effectiveness of drugs already in use. consume of patient-reported outcome data collected over the Internet offers advantages such as faster data collection, reduced cost and enhanced patient engagement; however, this approach moreover carries considerable risks in terms of color and, potentially, patient safety if it involves patient self-prescribing.Experimental approaches
Binding assays to identify target interactions. Proteomic techniques such as affinity chromatography and mass spectrometry savor been used as approaches to identify binding partners for an increasing number of drugs74. In an era of chemical biology for target validation, analyses of the targets and off-targets of drugs and drug repurposing savor become natural bedfellows. For example, the Cellular ThermoStability Assay (CETSA) technique has been introduced as a passage of mapping target rendezvous in cells using biophysical principles that predict thermal stabilization of target proteins by drug-like ligands that possess the confiscate cellular affinity75.
Examples of early successes with this technique include the confirmation of cellular targets for the tyrosine kinase inhibitor (TKI) crizotinib76 and the detection of quinone reductase 2 (NQO2) as a cellular off-target of acetaminophen (paracetamol)77. A necessity to address the promiscuity of protein kinase inhibitors has long been recognized78, and the prediction that protein kinases will portray the major drug targets of the 21st century79 may still be fulfilled. This has increased efforts to develop better probe compounds for preclinical research that can inform clinical drug development and repurposing through an evidence-based pharmacological 'audit trail' in cells80. It is moreover primary to note that the 'mistakes' made in various kinase drug discovery approaches savor much to contribute, and early-stage unbiased affinity approaches are particularly useful for understanding the likely effects of compounds in cells, which include paradoxical kinase activation by inhibitors81 that underlie mechanistic off-target tumour initiation in patients82. For example, to understand the complexity of compound effects, Brehmer and colleagues incubated HeLa cell lysate extracts with a matrix containing covalently attached gefitinib; mass spectrometry of the resultant elutes identified more than 20 different protein kinases as putative gefitinib targets74. Broader efforts savor moreover been employed to evaluate kinase inhibitors by employing affinity matrices containing 'kinobeads', which capture proteins before analytical quantification83, often revealing thoughtprovoking novel off-targets for well-known drugs84,85. Similar approaches savor now revealed many of the molecular on and off targets for primary clinical agents, such as the first-to-market (and relatively specific) BCR–ABL inhibitor imatinib86, which has been successfully repurposed to handle KIT-driven gastrointestinal stromal tumours87, the newer BCR–ABL inhibitors nilotinib and dasatinib, and the very promiscuous kinase inhibitor ponatinib.
Chemical genetics can moreover provide a better understanding of the relationship between binding and efficacy in the cellular context88. In turn, these findings can be rapidly translated into modern clinical areas or to address drug-resistance outcomes of prolonged exposure that are near-inevitable phenotypic responses to kinase inhibitor therapy in cancer89,90. Many of these studies stem from industry-driven high-throughput direct binding or catalytic assays, in which small-molecule–kinase binding is analysed in a kinome-wide fashion using a variety of in vitro and increasingly organism-based assays to generate heat maps of biologically primary interactions91,92. In one such study, Karaman and colleagues92 used an in vitro competition binding assay to evaluate 38 kinase inhibitors against a panel of 317 discrete human protein kinases; their analysis identified a total of 3,175 binding interactions. Interestingly, some kinase inhibitors such as sorafenib and dasatinib showed higher affinity to secondary kinase targets than their known primary target, potentially informing (or invalidating) their consume in patient populations. In the kinase realm in particular, non-kinase targets of little molecules originally designed to inhibit protein kinases are increasingly recognized93 and are leading to repurposing opportunities in cancer19, as Zika virus modulators94 and as potential agents to handle antibiotic-resistant microorganisms95.
Phenotypic screening. Phenotypic screening can identify compounds that exhibit disease-relevant effects in model systems without prior knowledge of the target(s) affected96. In the context of drug repurposing, if the compounds screened are approved or investigational drugs, this may bespeak repurposing opportunities that can readily be pursued. Typically, in vitro phenotypic screens consume a wide purview of cell-based assays in a 96-well format. For example, Iljin and colleagues97 conducted high-throughput cell-based screening of a library of 4,910 drug-like small-molecule compounds in four prostate cancer and two non-malignant prostate epithelial cell lines with proliferation as the primary conclude point. They identified disulfiram, a drug used for alcohol abuse, to be a selective antineoplastic agent, which was then validated using genome-wide gene expression studies. Whole-organism phenotypic assays are moreover utilized in drug repurposing; Cousin and colleagues98 used a zebrafish model to evaluate 39 FDA-approved medications for consume in tobacco dependence and establish that compounds such as apomorphine and topiramate modified nicotine-induced and ethanol-induced behaviour in this model.
3COM [8 Certification Exam(s) ]
AccessData [1 Certification Exam(s) ]
ACFE [1 Certification Exam(s) ]
ACI [3 Certification Exam(s) ]
Acme-Packet [1 Certification Exam(s) ]
ACSM [4 Certification Exam(s) ]
ACT [1 Certification Exam(s) ]
Admission-Tests [13 Certification Exam(s) ]
ADOBE [93 Certification Exam(s) ]
AFP [1 Certification Exam(s) ]
AICPA [2 Certification Exam(s) ]
AIIM [1 Certification Exam(s) ]
Alcatel-Lucent [13 Certification Exam(s) ]
Alfresco [1 Certification Exam(s) ]
Altiris [3 Certification Exam(s) ]
Amazon [2 Certification Exam(s) ]
American-College [2 Certification Exam(s) ]
Android [4 Certification Exam(s) ]
APA [1 Certification Exam(s) ]
APC [2 Certification Exam(s) ]
APICS [2 Certification Exam(s) ]
Apple [69 Certification Exam(s) ]
AppSense [1 Certification Exam(s) ]
APTUSC [1 Certification Exam(s) ]
Arizona-Education [1 Certification Exam(s) ]
ARM [1 Certification Exam(s) ]
Aruba [6 Certification Exam(s) ]
ASIS [2 Certification Exam(s) ]
ASQ [3 Certification Exam(s) ]
ASTQB [8 Certification Exam(s) ]
Autodesk [2 Certification Exam(s) ]
Avaya [101 Certification Exam(s) ]
AXELOS [1 Certification Exam(s) ]
Axis [1 Certification Exam(s) ]
Banking [1 Certification Exam(s) ]
BEA [5 Certification Exam(s) ]
BICSI [2 Certification Exam(s) ]
BlackBerry [17 Certification Exam(s) ]
BlueCoat [2 Certification Exam(s) ]
Brocade [4 Certification Exam(s) ]
Business-Objects [11 Certification Exam(s) ]
Business-Tests [4 Certification Exam(s) ]
CA-Technologies [21 Certification Exam(s) ]
Certification-Board [10 Certification Exam(s) ]
Certiport [3 Certification Exam(s) ]
CheckPoint [43 Certification Exam(s) ]
CIDQ [1 Certification Exam(s) ]
CIPS [4 Certification Exam(s) ]
Cisco [318 Certification Exam(s) ]
Citrix [48 Certification Exam(s) ]
CIW [18 Certification Exam(s) ]
Cloudera [10 Certification Exam(s) ]
Cognos [19 Certification Exam(s) ]
College-Board [2 Certification Exam(s) ]
CompTIA [76 Certification Exam(s) ]
ComputerAssociates [6 Certification Exam(s) ]
Consultant [2 Certification Exam(s) ]
Counselor [4 Certification Exam(s) ]
CPP-Institue [2 Certification Exam(s) ]
CPP-Institute [2 Certification Exam(s) ]
CSP [1 Certification Exam(s) ]
CWNA [1 Certification Exam(s) ]
CWNP [13 Certification Exam(s) ]
CyberArk [1 Certification Exam(s) ]
Dassault [2 Certification Exam(s) ]
DELL [11 Certification Exam(s) ]
DMI [1 Certification Exam(s) ]
DRI [1 Certification Exam(s) ]
ECCouncil [21 Certification Exam(s) ]
ECDL [1 Certification Exam(s) ]
EMC [129 Certification Exam(s) ]
Enterasys [13 Certification Exam(s) ]
Ericsson [5 Certification Exam(s) ]
ESPA [1 Certification Exam(s) ]
Esri [2 Certification Exam(s) ]
ExamExpress [15 Certification Exam(s) ]
Exin [40 Certification Exam(s) ]
ExtremeNetworks [3 Certification Exam(s) ]
F5-Networks [20 Certification Exam(s) ]
FCTC [2 Certification Exam(s) ]
Filemaker [9 Certification Exam(s) ]
Financial [36 Certification Exam(s) ]
Food [4 Certification Exam(s) ]
Fortinet [13 Certification Exam(s) ]
Foundry [6 Certification Exam(s) ]
FSMTB [1 Certification Exam(s) ]
Fujitsu [2 Certification Exam(s) ]
GAQM [9 Certification Exam(s) ]
Genesys [4 Certification Exam(s) ]
GIAC [15 Certification Exam(s) ]
Google [4 Certification Exam(s) ]
GuidanceSoftware [2 Certification Exam(s) ]
H3C [1 Certification Exam(s) ]
HDI [9 Certification Exam(s) ]
Healthcare [3 Certification Exam(s) ]
HIPAA [2 Certification Exam(s) ]
Hitachi [30 Certification Exam(s) ]
Hortonworks [4 Certification Exam(s) ]
Hospitality [2 Certification Exam(s) ]
HP [752 Certification Exam(s) ]
HR [4 Certification Exam(s) ]
HRCI [1 Certification Exam(s) ]
Huawei [21 Certification Exam(s) ]
Hyperion [10 Certification Exam(s) ]
IAAP [1 Certification Exam(s) ]
IAHCSMM [1 Certification Exam(s) ]
IBM [1533 Certification Exam(s) ]
IBQH [1 Certification Exam(s) ]
ICAI [1 Certification Exam(s) ]
ICDL [6 Certification Exam(s) ]
IEEE [1 Certification Exam(s) ]
IELTS [1 Certification Exam(s) ]
IFPUG [1 Certification Exam(s) ]
IIA [3 Certification Exam(s) ]
IIBA [2 Certification Exam(s) ]
IISFA [1 Certification Exam(s) ]
Intel [2 Certification Exam(s) ]
IQN [1 Certification Exam(s) ]
IRS [1 Certification Exam(s) ]
ISA [1 Certification Exam(s) ]
ISACA [4 Certification Exam(s) ]
ISC2 [6 Certification Exam(s) ]
ISEB [24 Certification Exam(s) ]
Isilon [4 Certification Exam(s) ]
ISM [6 Certification Exam(s) ]
iSQI [7 Certification Exam(s) ]
ITEC [1 Certification Exam(s) ]
Juniper [65 Certification Exam(s) ]
LEED [1 Certification Exam(s) ]
Legato [5 Certification Exam(s) ]
Liferay [1 Certification Exam(s) ]
Logical-Operations [1 Certification Exam(s) ]
Lotus [66 Certification Exam(s) ]
LPI [24 Certification Exam(s) ]
LSI [3 Certification Exam(s) ]
Magento [3 Certification Exam(s) ]
Maintenance [2 Certification Exam(s) ]
McAfee [8 Certification Exam(s) ]
McData [3 Certification Exam(s) ]
Medical [69 Certification Exam(s) ]
Microsoft [375 Certification Exam(s) ]
Mile2 [3 Certification Exam(s) ]
Military [1 Certification Exam(s) ]
Misc [1 Certification Exam(s) ]
Motorola [7 Certification Exam(s) ]
mySQL [4 Certification Exam(s) ]
NBSTSA [1 Certification Exam(s) ]
NCEES [2 Certification Exam(s) ]
NCIDQ [1 Certification Exam(s) ]
NCLEX [2 Certification Exam(s) ]
Network-General [12 Certification Exam(s) ]
NetworkAppliance [39 Certification Exam(s) ]
NI [1 Certification Exam(s) ]
NIELIT [1 Certification Exam(s) ]
Nokia [6 Certification Exam(s) ]
Nortel [130 Certification Exam(s) ]
Novell [37 Certification Exam(s) ]
OMG [10 Certification Exam(s) ]
Oracle [282 Certification Exam(s) ]
P&C [2 Certification Exam(s) ]
Palo-Alto [4 Certification Exam(s) ]
PARCC [1 Certification Exam(s) ]
PayPal [1 Certification Exam(s) ]
Pegasystems [12 Certification Exam(s) ]
PEOPLECERT [4 Certification Exam(s) ]
PMI [15 Certification Exam(s) ]
Polycom [2 Certification Exam(s) ]
PostgreSQL-CE [1 Certification Exam(s) ]
Prince2 [6 Certification Exam(s) ]
PRMIA [1 Certification Exam(s) ]
PsychCorp [1 Certification Exam(s) ]
PTCB [2 Certification Exam(s) ]
QAI [1 Certification Exam(s) ]
QlikView [1 Certification Exam(s) ]
Quality-Assurance [7 Certification Exam(s) ]
RACC [1 Certification Exam(s) ]
Real-Estate [1 Certification Exam(s) ]
RedHat [8 Certification Exam(s) ]
RES [5 Certification Exam(s) ]
Riverbed [8 Certification Exam(s) ]
RSA [15 Certification Exam(s) ]
Sair [8 Certification Exam(s) ]
Salesforce [5 Certification Exam(s) ]
SANS [1 Certification Exam(s) ]
SAP [98 Certification Exam(s) ]
SASInstitute [15 Certification Exam(s) ]
SAT [1 Certification Exam(s) ]
SCO [10 Certification Exam(s) ]
SCP [6 Certification Exam(s) ]
SDI [3 Certification Exam(s) ]
See-Beyond [1 Certification Exam(s) ]
Siemens [1 Certification Exam(s) ]
Snia [7 Certification Exam(s) ]
SOA [15 Certification Exam(s) ]
Social-Work-Board [4 Certification Exam(s) ]
SpringSource [1 Certification Exam(s) ]
SUN [63 Certification Exam(s) ]
SUSE [1 Certification Exam(s) ]
Sybase [17 Certification Exam(s) ]
Symantec [135 Certification Exam(s) ]
Teacher-Certification [4 Certification Exam(s) ]
The-Open-Group [8 Certification Exam(s) ]
TIA [3 Certification Exam(s) ]
Tibco [18 Certification Exam(s) ]
Trainers [3 Certification Exam(s) ]
Trend [1 Certification Exam(s) ]
TruSecure [1 Certification Exam(s) ]
USMLE [1 Certification Exam(s) ]
VCE [6 Certification Exam(s) ]
Veeam [2 Certification Exam(s) ]
Veritas [33 Certification Exam(s) ]
Vmware [58 Certification Exam(s) ]
Wonderlic [2 Certification Exam(s) ]
Worldatwork [2 Certification Exam(s) ]
XML-Master [3 Certification Exam(s) ]
Zend [6 Certification Exam(s) ]
Dropmark : http://killexams.dropmark.com/367904/11583321
Wordpress : http://wp.me/p7SJ6L-NK
Issu : https://issuu.com/trutrainers/docs/00m-648
Dropmark-Text : http://killexams.dropmark.com/367904/12114103
Blogspot : http://killexams-braindumps.blogspot.com/2017/11/dont-miss-these-ibm-00m-648-dumps.html
RSS Feed : http://feeds.feedburner.com/DontMissTheseIbm00m-648Dumps
weSRCH : https://www.wesrch.com/business/prpdfBU1HWO000TWME
Google+ : https://plus.google.com/112153555852933435691/posts/dw4BvqL5fbP?hl=en
Calameo : http://en.calameo.com/books/004923526ce74bff31e52
publitas.com : https://view.publitas.com/trutrainers-inc/dont-miss-these-ibm-00m-648-dumps
Box.net : https://app.box.com/s/3k8hgpemz7qy4fdcn678i2j0v7h87kky
zoho.com : https://docs.zoho.com/file/5psibb78e70ec256c40fab318f32438d56f47
is specialized in Architectural visualization , Industrial visualization , 3D Modeling ,3D Animation , Entertainment and Visual Effects .